Cultured seafood

01Overview and value chain

Markers: [EC: NACE 10.20 (Processing & preserving of fish, crustaceans & molluscs) | OECD: Food systems | Regulator: FDA (USA), EFSA (EU), MARA (CN)]

Cultured seafood — also called cell-cultured or cell-based seafood — is genuine fish, crustacean and mollusc muscle and fat tissue grown from a small biopsy of fish cells inside bioreactors, without catching or farming the whole animal. By decoupling seafood from fishing and aquaculture, the route relieves pressure on the roughly one-third of wild fish stocks that are overfished and sidesteps the fishmeal-to-farmed-fish conversion cost of conventional aquaculture, while preserving the omega-3 and protein profile of conventional fish at 18–25 grams of protein per 100 g. Wildtype’s 2024 FDA “no questions” letter for its cell-cultivated coho salmon made it the first cultivated seafood cleared for US sale and only the third cultivated protein after Upside Foods and Good Meat. Production today sits at pilot scale in 500–2,000-litre bioreactors, with fish cell-line development and serum-free marine media the binding economics on the path toward 10,000-litre commercial capacity.

The key directions of cultured seafood are:

1. Fish cell-line development: isolating and immortalising muscle and fat cell lines from salmon, tuna, grouper and other species that divide indefinitely without fetal bovine serum.
2. Animal-free marine media: replacing bovine serum with plant- or microbe-derived amino-acid and growth-factor formulations tuned to fish-cell metabolism — the single largest cost driver.
3. Bioreactor scale-up (perfusion / stirred-tank): expanding fish cells from the flask to 500–2,000-litre pilot vessels and toward 10,000-litre food-grade commercial systems.
4. Structured whole-muscle & sashimi-grade texture: seeding cells on scaffolds to reproduce fish fillet, steak and sashimi-grade texture that minced or hybrid products cannot reach.

Sectoral value chain

[Fin biopsy & cell banking] ──> [Marine media] ──> [Cell expansion] ──> [Differentiation]
                                                        │
                                                (Scaffold seeding)
                                                        │
                                                        ▼
[Food service & retail] <─── [Structuring & harvest] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Fish animal-cell culture: aseptic propagation of piscine muscle, fat and stem cells in controlled, food-grade bioreactors outside the living fish.
• Food-grade perfusion bioreactors: continuous stirred-tank and hollow-fibre systems that refresh serum-free media and harvest fish biomass at high cell density.
• Tissue scaffolding: edible or removable fibre, hydrogel and 3D-printed matrices that organise fish cells into fillet- and sashimi-grade architecture.

02US

The United States leads cultured seafood, with the FDA’s first cultivated-seafood clearance and the deepest cluster of cell-line, media and scale-up companies.

First FDA clearance, tuna toro, sushi-grade bluefin

• Wildtype: the San Francisco company whose cell-cultivated coho salmon received an FDA “no questions” letter in 2024, making it the first cultivated seafood cleared for US sale and the third cultivated protein after Upside Foods and Good Meat, with the product debuted on US restaurant menus.
• BlueNalu: the San Diego developer of a non-GMO fish-cell-propagation platform for premium bluefin tuna toro, which has raised roughly $129 million (including a recent $11 million round) from Agronomics, Siddhi Capital, Lewis & Clark AgriFood and about 40 strategic food-industry investors.
• Finless Foods: a Berkeley pioneer developing sushi-grade cultivated Pacific bluefin tuna, financing its 2025 launch pathway through regulated investment crowdfunding alongside ongoing institutional backing.

03CN

China’s cultured-seafood activity is concentrated in the Greater China–Singapore corridor, where a Hong Kong front-runner and a Singapore regulatory hub frame the regional pathway.

Greater-China pioneers, Singapore hub, grouper and eel lines

• Avant Meats: a Hong Kong cultivated-seafood company growing grouper, snapper and eel cells in a Singapore pilot plant, which had planned a 30-fold capacity expansion; it is restructuring its Singapore operations while continuing to pursue regulatory approval in the city-state.
• Shiok Meats: a Singapore pioneer of cell-cultivated crustaceans — shrimp, lobster and crab — that is merging with Umami Bioworks to pool cell-line and scale-up assets for the Asia-Pacific market.
• Singapore as regulatory hub: Singapore’s 2020 cultivated-meat approval made the city-state the regional launchpad for cell-based seafood, anchoring pilot plants and tastings for several Greater-China and European players.
• Aquaculture research base: China’s large aquaculture and marine-biology research base underpins future domestic cell-line and media work, with the MARA pathway defining the novel-food route for cell-based aquatic products.

04EU

Europe’s cultured-seafood effort is led by a German Fraunhofer spinout building the continent’s first dedicated facility, under the EFSA novel-food framework.

Fraunhofer spinout, Hamburg pilot facility, EFSA pathway

• Bluu Seafood: a Lübeck company spun out of the Fraunhofer Institute by marine biologist Sebastian Rakers and start-up expert Simon Fabich, with a team of 33 from 12 countries, running Europe’s first dedicated cultivated-seafood facility in Hamburg and scaling from 500-litre to 2,000-litre bioreactors to grow Atlantic salmon and rainbow-trout cells into fish balls and fish fingers, targeting a 2025 Singapore launch.
• Hybrid product strategy: European players blend fish-cell biomass with plant proteins to reach workable texture, cost and regulatory footing ahead of pure whole-tissue products.
• EFSA novel-food pathway: the EU reviews each novel ingredient individually, framing a multi-year approval route that shapes how European cultivated-seafood firms sequence their market entry.

05Leading companies and research institutes

06Tech stack and innovations

Cultured seafood adapts vertebrate cell-culture, food-grade bioreactor engineering and tissue structuring to fish cells, where omega-3-rich lipid biology and sashimi-grade texture set the technical bar.

1. Fish cell-line & serum-free media engineering:
   • Immortalised fish muscle and fat cell lines — from coho salmon, bluefin tuna, grouper and eel — are selected to divide indefinitely without fetal bovine serum, removing a cost and an animal-ethics burden.
   • Serum-free marine media are the dominant cost driver; firms tune amino-acid and growth-factor formulations to fish-cell metabolism to drag unit cost toward parity with farmed fish.
2. Food-grade perfusion bioreactors:
   • Continuous perfusion with tangential-flow filtration sustains high fish-cell densities and daily harvest, with Bluu Seafood scaling from 500-litre to 2,000-litre pilot vessels toward 10,000-litre commercial capacity.
   • Food-grade, non-GMO supply chains are a defining requirement for seafood regulators, shaping both reactor design and media inputs.
3. Scaffold & sashimi-grade structuring:
   • Edible fibre and hydrogel scaffolds organise differentiated fish cells into aligned fillet and steak architecture, and ultimately the sashimi-grade texture that premium tuna-toro and salmon products command.

07Value chains and production pipelines

Industrial pipeline of cultured-seafood manufacturing (HACCP / ISO 22000 food-safety standards)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Fin biopsy & cell bank │ ───> │ 2. Marine media           │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Differentiation        │ <─── │ 3. Cell expansion         │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Structuring & harvest  │ ───> │ 6. Formulation & sales    │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Fin biopsy & cell banking

A small fin or fry-stage tissue sample is taken from a food fish, and muscle and fat progenitor cells are isolated, characterised and banked as a master fish cell line that supplies all downstream production without further fish.

Stage 2: Marine media formulation

A serum-free nutrient broth of amino acids, lipids, salts, vitamins and fish-relevant growth factors is compounded from plant or microbial sources, replacing fetal bovine serum and setting both the cost and the omega-3 profile of the final seafood.

Stage 3: Cell expansion

Seed cells are grown in food-grade stirred-tank or perfusion bioreactors scaled from a few litres to 500–2,000-litre pilot capacity, with continuous media refresh and tangential-flow filtration sustaining high cell densities for daily biomass harvest.

Stage 4: Differentiation

Fish progenitor cells are switched to maturation media that drives them into contractile muscle fibres and lipid-rich adipose tissue, reproducing the two cell populations that define the taste, texture and omega-3 content of seafood.

Stage 5: Structuring & harvest

Differentiated cells are seeded onto edible fibre or hydrogel scaffolds and matured into fillet-, steak- or sashimi-grade structures, then harvested and checked against food-safety specifications.

Stage 6: Formulation & sales

Structured tissue is blended with plant proteins where needed and shaped into finished products — sashimi cuts, fillets, fish balls or fish fingers — then packaged, labelled under the applicable FDA, EFSA or MARA pathway, and distributed to restaurants and retail.